About Us

Evolving Medicines, Empowering Lives

We’re an innovative company with great ambition to develop value-added medicines and treatment options that empower patients’ lives. We’re experts in repurposing medicines, transforming existing molecules, and optimising existing therapies.

Our dedicated team carries out meticulous research and data analysis to identify and understand areas where we can transform existing molecules into valuable medicines. By identifying and recognising unmet clinical needs, we develop innovative solutions that make medicines tailored to support patient needs to improve their clinical outcomes and quality of life.

Our Values

We Are Allies

Patients are our priority. By actively listening and understanding where there is an unmet clinical need, we create new and alternative options that advocate for patients who need us the most.

We Step Beyond

Rethinking the conventional, we relentlessly pursue creative solutions that evolve the limits of what was once thought possible.

We are Smarter

We see the unseen, recognising unique opportunities to swap the norm for a new treatment option.

We are Tenacious

We make a bigger impact by elevating product value for practitioners and for patients.

Our Four Key Pillars

At Colonis, everything we do is centred around four key pillars:

Patient Centricity

Patients remain at the centre of everything we do. Our commitment extends beyond traditional generic product licensing and commercialisation and focuses on fully understanding the unmet clinical needs, including patients’ unique journeys, aspirations, and the challenges they face. By actively listening to clinicians, clinical pharmacists, prescribers, and patient and professional groups, we can develop solutions that directly address their individual needs and preferences.

Innovation and Research

Our business model prioritises innovation, research, and development. By pushing the boundaries of repurposing, we seek to unlock new possibilities for clinicians and patients alike. We actively collaborate with healthcare professionals, academia, and other industry partners to accelerate breakthroughs and translate them into tangible advancements that positively impact patients’ lives.

Product Development

We are dedicated to continuously advancing our product portfolio. Our commitment to rigorous and efficient product development processes, which consistently meet needs for unique requirements, enables us to bring value-added medicines to market. Applying robust regulatory compliance, and conducting ongoing monitoring, we deliver high-quality value-added medicines.

Collaboration and Partnerships

We believe that achieving our vision requires collaboration and strategic partnerships to develop our portfolio so that we can enable patients and healthcare professionals access to medicines that meet unmet clinical needs. We actively seek partnerships that align with our values and enable us to amplify our impact, expand access to our portfolio of products, and maximise patient outcomes.

Meet the Team

Read Bio

Quality Assurance Officer

Andreea Moldovanu

Read Bio

Quality Manager

Andrew Lumsden

Read Bio

Managing Director

Andrew Trouton

Read Bio

National Account Manager

Derek Lilley

Read Bio

Product Manager

Fiona Wiles

Read Bio

Commercial Director

Michael Dobson

Read Bio

New Product Business Development Manager

Narendra Patel

Read Bio

Finance Director

Patty Efraimidou

Read Bio

Head of Supply Chain

Penny Ralph

Read Bio

Alliance and Business Development Manager

Suzie Stratford

Read Bio

Regulatory Affairs Director

Vamshee Juvadi

Read Bio

Market Analyst

Yulia Richmond

If you would like to speak to someone from the team, please visit our contact page

Andreea Moldovanu
– Quality Assurance Officer

Andreea joined Colonis in 2023 as our Quality Assurance Officer. With a background supporting Pharmaceutical Quality, she specialises in overseeing the compliance (GMP/GDP) of training and documentation related activities associated with our drug product range across the business. Andreea also supports the vendor management process alongside communications with suppliers, internal and external customers related to quality issues.

Andrew Lumsden – Quality Manager
Andrew has been the Quality Lead for Colonis’ value-added medicines portfolio since 2019, overseeing UK, EU, and RoW markets. With over 30 years of international pharmaceutical quality control experience, Andrew brings extensive expertise to his role, working closely with his team to oversee the compliance of products throughout their lifecycle and ensure safe, continuous medicine supply to patients.
Andrew Trouton – Managing Director
With over 35 years of experience in the pharmaceutical industry across brands, generics and unlicensed medicines, Andy guides the strategic direction of the Colonis team, providing leadership through development and commercialisation of novel value-added medicines.
Derek Lilley – National Account Manager
Derek joined Colonis in 2023 as National Account Manager, overseeing UK commercial activities and strategy of the Colonis portfolio. He brings with him 12 years of pharmaceutical industry experience in the retail and hospitals sectors, promoting generic and branded generic medicines across numerous therapy areas including Oncology, Anti-infectives, Cardiovascular, Respiratory and Pain.
Fiona Wiles – Product Manager
Since joining the Colonis team in 2019 as a Product Manager, Fiona has leveraged her 20 years of pharmaceutical experience to oversee and expand the Colonis product portfolio in the UK and other territories. She is responsible for planning and managing commercials, budgets, marketing and medical education strategies as well as campaigns for key products and launches.
Michael Dobson – Commercial Director
Michael joined Colonis as Commercial Director in 2014. With 12 years of pharmaceutical industry experience across various roles in commercial, marketing, and product management, he currently oversees the global commercial strategy for the Colonis business.
Narendra Patel – New Product Business Development Manager
Narendra joined the Colonis team as New Product Business Development Manager in 2021. With over 12 years of pharmaceutical experience, he specialises in value-added portfolio planning and licensing and holds degrees in Pharmacy, Pharmaceutical Science and an MBA.
Patty Efraimidou – Finance Director
With over 20 years of financial experience, Patty joined Colonis as Finance Director in 2017. In her day-to-day role, Patty directs and oversees all aspects of the finance and accounting functions, from supporting the management team in maximising assets and investments, to providing robust and insightful support on key business decisions.
Penny Ralph – Head of Supply Chain
With over 30 years of experience in procurement and supply chain, Penny has been with Colonis since 2005. Her expertise lies across clinical trial procurement, unlicensed global supply, system implementation, and commercial medicines supply chain. Currently, Penny manages the Colonis supply chain, which includes planning, procure to pay, logistics, and new product introduction. She is also an associate member of the Chartered Institute of Purchasing and Supply.

Suzie Stratford
– Alliance and Business Development Manager

Suzie joined the Colonis team in 2023 as our Alliance and Business Development Manager.
She holds an MA in International Business Management and brings with her four years of pharmaceutical industry experience, having previously focused on licensing deals for value-added and branded generic medicines in a range of therapeutic areas. Suzie is responsible for the management of our international partner network and expanding the Colonis product portfolio into global markets.

Vamshee Juvadi – Regulatory Affairs Director
With over 15 years of experience in quality control, research development and regulatory affairs, Vamshee has been Colonis’ Regulatory Affairs Director since 2018. He guides product development through European and international regulatory processes and specialises in development strategies, including preparation, planning, and participation in scientific advice meetings with regulatory agencies. Vamshee also offers insights on in-licensing opportunities and acquisitions, leveraging his background as a trained pharmacist.
Yulia Richmond – Market Analyst
Yulia joined Colonis as a Market Analyst in 2019, where she specialises in analysing product market competition, forecasting future sales, and conducting scenario modelling and sensitivity analysis.

You are now leaving

You are now leaving the Colonis website and being redirected to a Clinigen Group website.

Click “Cancel” to remain on the Colonis website.
Click “Continue” to visit the Clinigen website.

You are now leaving

You are now leaving the Colonis website and being redirected to a Clinigen Group website.

Click “Cancel” to remain on the Colonis website.
Click “Continue” to visit the Clinigen website.

You are now leaving

You are now leaving the Colonis website and being redirected to a Clinigen Group website.

Click “Cancel” to remain on the Colonis website.
Click “Continue” to visit the Clinigen website.

You are now leaving

You are now leaving the Colonis website and being directed to an external website for which Colonis is not responsible.

Click “Cancel” to remain on the Colonis website.
Click “Continue” to visit the external website.

You are now leaving

You are now leaving the Colonis website and being directed to an external website for which Colonis is not responsible.

Click “Cancel” to remain on the Colonis website.
Click “Continue” to visit the external website.